D. Boral Capital Reaffirms “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 103.42% from the stock’s previous close.

Several other equities analysts have also weighed in on URGN. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. Guggenheim began coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, UroGen Pharma currently has a consensus rating of “Buy” and an average target price of $43.70.

UroGen Pharma Stock Up 0.7 %

Shares of URGN opened at $12.29 on Friday. UroGen Pharma has a fifty-two week low of $10.60 and a fifty-two week high of $20.70. The company’s fifty day moving average is $12.28 and its two-hundred day moving average is $13.96. The firm has a market cap of $288.20 million, a PE ratio of -3.90 and a beta of 1.06. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the previous year, the business posted ($0.68) EPS. Analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current year.

Hedge Funds Weigh In On UroGen Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of URGN. China Universal Asset Management Co. Ltd. lifted its position in shares of UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after purchasing an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets increased its stake in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after buying an additional 5,890 shares during the period. ProShare Advisors LLC acquired a new position in UroGen Pharma in the 2nd quarter worth $199,000. Intech Investment Management LLC acquired a new position in UroGen Pharma in the 3rd quarter worth $155,000. Finally, Verition Fund Management LLC purchased a new position in UroGen Pharma in the 3rd quarter valued at about $168,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.